Evidence map›Paper›PMID 28111598›Full record

ArticleJournal of microbial & biochemical technology2016

The mPEG-PCL Copolymer for Selective Fermentation of Staphylococcus lugdunensis Against Candida parapsilosis in the Human Microbiome.

Ming-Shan Kao, Yanhan Wang, Shinta Marito, Stephen Huang, Wan-Zhen Lin, Jon A Gangoiti, Bruce A Barshop, Choi Hyun, Woan-Ruah Lee, James A Sanford and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of microbial & biochemical technology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Microbe Interactions within the Skin Microbiome.Antibiotics (Basel, Switzerland) · 2024
    Review
  2. Article
  3. Probiotic Activity ofInternational journal of molecular sciences · 2021
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Ming-Shan KaoDepartment of Life Sciences, National Central University, Taoyuan, Taiwan.
Yanhan WangDepartment of Dermatology, University of California, San Diego, CA, USA.
Shinta MaritoDepartment of Life Sciences, National Central University, Taoyuan, Taiwan.
Stephen HuangSurface Bioadvances Inc., San Diego, CA, USA.
Wan-Zhen LinDepartment of Life Sciences, National Central University, Taoyuan, Taiwan.
Jon A GangoitiDepartment of Pediatrics University of California, San Diego, CA, USA.
Bruce A BarshopDepartment of Pediatrics University of California, San Diego, CA, USA.
Choi HyunDepartment of Pediatrics University of California, San Diego, CA, USA.
Woan-Ruah LeeDepartment of Dermatology, Taipei Medical University, Taipei, Taiwan.
James A SanfordDepartment of Dermatology, University of California, San Diego, CA, USA.
Richard L GalloDepartment of Dermatology, University of California, San Diego, CA, USA.
Yuping RanDepartment of Dermatology, West China Hospital, Sichuan University, Chengdu, China.
Wan-Tzu ChenDepartment of Biomedical Engineering, Chung Yuan Christian University, Taoyuan, Taiwan.
Chun-Jen HuangDepartment of Biomedical Sciences and Engineering, National Central University, Taoyuan, Taiwan.
Ming-Fa HsiehDepartment of Biomedical Engineering, Chung Yuan Christian University, Taoyuan, Taiwan.
Chun-Ming HuangDepartment of Dermatology, University of California, San Diego, CA, USA; Moores Cancer Center; University of California, San Diego, CA, USA.
National Central University · TWUniversity of California, San Diego · US

Funding

Dysbiotic Rebalancing with S. epidermidis Fermentation in Acne VulgarisR41AR065260 · NIAMS · SURFACE BIOADVANCES, INC. · PI HUANG, CHUN-MING · 2015 to 2015
$150k
NIAMS NIH HHS R41 AR065260
6 · The paper itself

Abstract

Many human skin diseases, such as seborrheic dermatitis, potentially occur due to the over-growth of fungi. It remains a challenge to develop fungicides with a lower risk of generating resistant fungi and non-specifically killing commensal microbes. Our probiotic approaches using a selective fermentation initiator of skin commensal bacteria, fermentation metabolites or their derivatives provide novel therapeutics to rein in the over-growth of fungi.

Indexed as

C. parapsilosisFermentationMicrobiomeProbioticS. lugdunensis

Identifiers

PMID28111598
PMCPMC5243119
OpenAlexW2525237621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.